Research Sample bioBank

Can’t find what you’re looking for? Contact us.

Or, need help ordering? 805.528.4341

Filter Samples By:

Get Weekly Research Sample Updates in your Inbox:

Heart Failure Clinical Research Samples

Discovery Life Sciences provides the highest quality Heart Failure Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank. 

  • All Heart Failure Sample Orders are Packaged for Delivery within 24 Hours. 
  • All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
  • Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
  • Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations. 
Showing 78 of 78 total samples
 (0)
Checkout
Advanced Data View:
Showing 78 of 78 total samples
Buy
Product IDSampleOriginMatrixVial (ml)QuantityPriceAgeGenderEthnicityStorage TempSample DateTest 1Test Data 1Detail 1Test 2Test Data 2Detail 2Test 3Test Data 3Product
Details
Price
Buy
Blood TypeCurrent MedicationsHeightClinical DiagnosisComorbidities | Treatment of ComorbiditiesECG | HeartLaboratory ResultsCT-Scan | ChestX-Ray | ChestСoronarography | HeartLaboratory Results | BloodOphthalmoscopy | EyesUltrasound | Abdominal cavityCoronary angiography | HeartX-Ray | HeartPhysical Exam | Abdominal cavity & LegsBiochemical Analysis | BloodHolter Monitor | HeartAbbott Architect | CMIA | Chemiflex
BBS0000-A0900108476090519DDHeart FailureSerum1.0010.00$200.0059 YFemaleNon-Hispanic<-70C05-Sep-19ECG | Heart140/90Laboratory resultsC-reactive protein (CRP) - 30.11 mg/l; Creatine Kinase - MB (CPK-MB) - 19 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 171.7 pg/ml5-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownN/A164 cm 72 kgIschemic heart disease: cardiosclerosis, Heart failure, grade I. Functional class, grade II (NYHA).Essential hypertension, grade II 02/01/2014
Enap-H (Enalaprilum, Hydrochlorothiazide) 02/01/2014
BBS0000-A0900108478082719DDHeart FailureSerum1.0013.00$200.0064 YFemaleNon-Hispanic<-70C27-Aug-19ECG | Heart140/90The sinus rhythm is correct, the heart rate is 75 beats per minute. Segment elevation st.Laboratory resultsC-reactive protein (CRP) -30.3 mg/l; Creatine Kinase-MB (CPK-MB) - 9 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 1277 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownClopidogrel 75 mg, Aspirin 75 mg, Enoxaparin 0.6 ml, Rosuvastatin 40 mg, Ramipril 10 mg164 cm 99 kgIschemic heart disease:acute myocardial infarction (8/14/2019) back wall of the left ventricle. Stenting of the right coronary artery (8/14/2019). Mitral valve insufficiency, stage II-III, Aortic valve insufficiency, stage I. Heart failure, grade IIA, Functional class, grade III (NYHA) with preserving the ejection fraction left ventricle. Hypertensive disease grade III, stage III, risk IV.Acute cerebral impairment by ischemic type 01/01/2013, Acute cerebral impairment by ischemic type 01/01/2017, Diabetes mellitus, type II 01/01/2018
Tiogamma, Sermion, Metformin 850 mg
Sinus rhythm, heart rate 67 beats per minute. The horizontal position of the electric axis. Dynamic changes in the myocardium.
22-Aug-19
Left ventricular myocardial hypertrophy. Enlarged right ventricle. Mitral valve insufficiency, stage III, tricuspid valve, stage I-II, aortic valve, stage I. Probability of arterial hypertension of the heart. Aortocardiosclerosis.
15-Aug-19
8/15/2019 - Troponin T - 1.012 ng/ml; 8/16/2019 - Troponin T - 0.844 ng/ml
15-Aug-19
BBS0000-A0900108481082719DDHeart FailureSerum1.0012.00$200.0076 YMaleNon-Hispanic<-70C27-Aug-19ECG | Heart120/80End-diastolic size of the left ventricle 6.2; End systolic size 4.9; end-diastolic volume 199; final systolic volume 114. Left ventricular myocardial contractility reduced, left ventricular hypertrophyLaboratory resultsC-reactive protein (CRP)-2.23 mg/l; Creatine kinase-MB (CPK-MB) -13 U/l; Troponin I- <0.1 ng/ml; NT-proBNP- 1577 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownRenial 50 mg, Warfarinum 6.25 mg, Corvasan (Carvedilоlum) 3.125 mg, Livostor (Atorvastatinum) 10 mg, Torasemide 10 mg180 cm 90 kgIschemic heart disease: diffuse and post-infarction cardiosclerosis. Permanent form of atrial fibrillation. Blockade of the left bundle branch block. Heart failure, grade IIA, Essential hypertension, grade III, stage II. Functional class III (NYHA).N/A
N/A
Atrial fibrillation with a heart rate of 109/67 beats / min, left ventricular hypertrophy, complete blockade of the left bundle branch block
12-Aug-19
BBS0000-A0900108482083019DDHeart FailureSerum1.0015.00$200.0053 YMaleNon-Hispanic<-70C30-Aug-19ECG | Heart100/60Cavities are expanded, ES-26%Laboratory resultsC-reactive protein (CRP) - 2.57 mg/l; Creatine Kinase-MB (CPK-MB) - 8 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 2686 pg/ml30-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownVerospiron (Spironolactone) 50 mg, Torasemide 5-10 mg, Bravadin 10 mg, Warfarinum 10 mg180 cm 91 kgDiffuse myocarditis with a transition to dilated cardiomyopathy. Mitral valve insufficiency grade III, tricuspid insufficiency grade II. Pulmonary hypertension of the 2nd degree. Bilateral hydrothorax. Thromboembolism of the upper lobar pulmonary artery (July 11, 2019), Heart failure, grade IIB with reduced ejection fraction of left ventricular, functional class, grade III-IV (NYHA).Thromboembolism of the left upper pulmonary artery Cyst of the right kidney Ventricular extrasystole
Geparin, Flenoks, Corvitin (Quercetin), T-triomax (Salt morfolinicum of acidum tiazoticum)
Sinus rhythm irregular, ventricular extrasystole is overloaded.
22-Jul-19
Extrasystolic arrhythmia. Expansion of all cavities of the heart. Mitral insufficiency, stage II-III. Tricuspid insufficiency, stage II. Moderate pulmonary hyperplasia. Systodiastolic left ventricular dysfunction.
22-Aug-19
Thromboembolism of the left upper pulmonary artery. Bilateral hydrothorax.
11-Jul-19
BBS0000-A0900108484090319DDHeart FailureSerum1.0011.00$200.0070 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart160/90Arterial changes in the aorta, coronary heart disease, dilatation of the heart cavity. Reduced ejection fraction.Laboratory resultsC-reactive protein (CRP) -13.3 mg / l; Creatine Kinase - MB (CPK-MB) -5 U/l; Troponin I <0.1ng / ml; NT-proBNP-1052 pg / ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownN/A182 cm 90 kgIschemic heart disease: cardiosclerosis; Heart failure, grade I. Functional class, grade II (NYHA).Bilateral lower lobar pneumonia 08/11/2019
Zacef (Ceftazidime)
BBS0000-A0900108543082819DDHeart FailureSerum1.0015.00$200.0069 YFemaleNon-Hispanic<-70C28-Aug-19ECG | Heart160/100Sinus rhythm is normal, the position of the electrical axis of the heart, frequent atrial extrasystole.Laboratory resultsC-reactive protein (CRP) -58.93 mg/l; Creatine Kinase-MB (CPK-MB) - 14 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 984.5 pg/ml28-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownEnalozid (Enalapril, hydrochlorothiazide) 10 mg, Sydnopharm (Molsidominum) 2 mg, Rosart (Rosuvastatinum) 20 mg, Asparcam N/A, Rytmonorm 200 mg165 cm 70 kgIschemic heart disease: diffuse cardiosclerosis. Aortic valve stenosis. Mitral valve insufficiency, frequent extrasystole. Heart failure, grade II, Functional class, grade II (NYHA)Rheumatoid arthritis 01/01/2018
Methylprednisolone 01/01/2018
Left ventricular myocardial hypertrophy, myocardial contractility is not impaired. Mitral valve insufficiency, stage I-II. Atherosclerosis of the aorta. Aortic stenosis, stage II.
5/24/2019
BBS0000-A0900108544090519DDHeart FailureSerum1.0014.00$200.0068 YFemaleNon-Hispanic<-70C05-Sep-19ECG | Heart130/90Fibrosclerotic valve changes, expansion of the right ventricle, diastolic dysfunction.Laboratory resultsC-reactive protein (CRP) -2.55 mg/l; Creatine Kinase-MB (CPK-MB) - 13 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 376.7 pg/ml5-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownSpironolactonum 25 mg, Torasemide 10 mg, Bisoprolol 5 mg, Valsartan 160 mg165 cm 71 kgIschemic heart disease:cardiosclerosis. Mitral valve insufficiency, stage I. Atrial fibrillation. Arterial hypertension, grade II, stage I-II, risk II. Moderate myocardial hypertrophy. Heart failure, grade I. Functional class, grade II (NYHA).Coronary heart disease with persistent atrial fibrillation. 01/01/2016, Hypertension, stage II 01/01/2010, Chronic pancreatitis in remission 01/01/2008
Bisoprolol 01/01/2017, Difors (Valsartan, Amlodipine ) 01/01/2017
Sinus rhythm regular, signs of enlargement of the left ventricle.
1-Apr-16
Paroxysmal tachyarrhythmia with a reduced ejection fraction. Systolic dysfunction of the left ventricle.
10-May-17
Compared with echocardiography from 3/21/2016 without significant dynamics.
5-Sep-19
BBS0000-A0900108547090319DDHeart FailureSerum1.0014.00$200.0078 YFemaleNon-Hispanic<-70C03-Sep-19ECG | Heart130/80Aorta-3.2; Aortic valve-regurgitation (+); Left atrium-3.3; Left ventricle-4.5; Walls-1.0; Interventricular septum-1.3; EF-45%.Laboratory resultsC-reactive protein (CRP) -2.7 mg/l; Creatine Kinase-MB (CPK-MB) - 9 U/l; Troponin I <0.1ng / ml; NT-proBNP - 6053 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownKsarelto 20 mg165 cm 82 kgPulmonary embolism. Heart failure, grade IIA. Functional class III (NYHA).Essential hypertension 01/01/2006, Myocardial infarction Phlebothrombosis
Plavix (Clopidogrel) 08/30/2019, Atorvacor (Atorvastatinum) 08/15/2019, Pantasun (Pantоprazole) 08/15/2019, Diocor (Valsartan, Hidrochlorothiazide) 08/15/2015
The sinus rhythm is correct. Heart rate 62 beats per minute. Signs of acute anterior septal myocardial infarction.
20-Aug-19
BBS0000-A0900108550090319DDHeart FailureSerum1.0015.00$200.0056 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart160/110R. coronary artery: stenosis of first portion 60-65%, stent of second portion, permanent restenosis up to 65%, blood flow TIMI IIILaboratory resultsC-reactive protein (CRP) -1.53 mg / l; Creatine Kinase-MB (CPK-MB) - 9 U/l; Troponin I <0.1ng / ml; NT-proBNP-165.40 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCorvitin (Quercetin) 0.5 g, Vasopro (Mildronate) 5.0 ml, Spironolactonum 25 mg, Nebivolol 10 mg, Effox long 50 mg184 cm 95 kgIschemic heart disease: Angina pectoris, Functional class, grade III. Postinfarction (1/22/2018). Cardiosclerosis-coronary ventriculography (1/23/2018), stenting -stage, II of the left coronary artery. Repeated coronoventriculography (8/27/2018). Essential hypertension, grade III, stage III. Heart failure, grade IIA, preserving the ejection fraction 64%. Functional class, grade II-III (NYHA).Gout. Arthritis of the knee in remission. N/A, Arterial hypertension, grade III, stage III 01/01/2016, Ischemic heart disease 01/22/2018
Diocor solo (Valsartan) 01/01/2016, Lospirin (Acetylsalicylic acid) 01/22/2018, Nebivolol 01/22/2018, Plavix (Clopidogrel) 01/23/2018, Roksera 01/23/2018
Sinus rhythm is regular, the deviation of the electrical axis of the heart to the left.
2-Sep-19
Dilation of the left departments of the heart, right ventricle. Hypertrophy of the walls of the left ventricle, systodiastolic dysfunction of the left ventricle. Atherosclerosis.
17-Sep-18
BBS0000-A0900108551091019DDHeart FailureSerum1.0014.00$200.0050 YMaleNon-Hispanic<-70C10-Sep-19ECG | Heart155/85Laboratory resultsC-reactive protein (CRP) - 77.58 mg/l; Creatine Kinase - MB (CPK-MB) - 6 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 45.54 pg/ml10-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCarvedilol 6.25 mg184 cm 96 kgIschemic heart disease. Heart failure, grade I. Functional class, grade II (NYHA).N/A
N/A
BBS0000-A0900108739082719DDHeart FailureSerum1.0013.00$200.0066 YMaleNon-Hispanic<-70C27-Aug-19ECG | Heart125/90Sinus rhythm with heart rate of 90 beats per minute. Ventricular extrasystole, blockade of the anterior branch of the left bundle branch.Laboratory resultsC-reactive protein (CRP) -23.93 mg /l; Creatine Kinase-MB (CPK-MB) - 7 U/l; Troponin I 0.338 ng/ml; NT-proBNP - 1144 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCardiket retard(Isosorbidi dinitros) 20 mg, Dikor-long 40 mg, Korvazan 12.5 mg, Torsid (Torasemide) 5 mg, Trombonet (Clopidogrelum) 75 mg, Spironolactonum 50 mg166 cm 100 kgIschemic heart disease. Exertional angina, Functional class, grade III. Post-infarction cardiosclerosis (2013) with hypokinesis of the walls of the left ventricle, its diastolic dysfunction (EF-35%). Heart failure, grade IIB, Functional class, grade III (NYHA).Subarachnoid hemorrhage 01/01/2001, Essential hypertension, grade II, stage III 01/01/1997
Amlodipin (Amlodipinum) 01/01/2017
Left atrium-100cm^3; Final diastolic size of the left ventricle-7.3cm; Final diastolic volume-260cm^3 ginokinesis of the walls of the left ventricle; EF-35%.
19-Aug-19
Congestive changes in the pulmonary circulation. Basal pneumofibrosis
20-Aug-19
BBS0000-A0900108740082719DDHeart FailureSerum1.0015.00$200.0050 YFemaleNon-Hispanic<-70C27-Aug-19ECG | Heart100/60Stenosis of the left atrioventricular opening, stage III. Regurgitation mitral valve, stage II. Aortic valve insufficiency, stage II. Relative tricuspid insufficiency, stage II. Systolic function of the left ventricular myocardium is not impaired.Laboratory resultsC-reactive protein (CRP) -0.98 mg/l; Creatine Kinase-MB (CPK-MB) -12 U/l; Troponin I <0.1 ng/ml; NT-proBNP-1094 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBisoprolol 2.5 mg, Cardiomagnyl (Acetylsalicylic acid) 75 mg, Berlipril (Enalapril) 5 mg166 cm 64 kgChronic rheumatic heart disease, stage I. Mitral valve stenosis, stage III. Aortic valve insufficiency, stage II. – Heart failure, grade I, Functional class, grade II (NYHA).N/A
N/A
Sinus tachycardia. Ventricular extrasystole.
23-Aug-19
BBS0000-A0900108741082819DDHeart FailureSerum1.0013.00$200.0056 YMaleNon-Hispanic<-70C28-Aug-19ECG | Heart120/80Laboratory resultsC-reactive protein (CRP) -0.32 mg/l; Creatine Kinase-MB (CPK-MB) - 23 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 625.90 pg/ml28-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownClopidogrel 75 mg, Etset 20 mg, Valodip ( Amlodipine + Valsartan) 5/80 mg, Ksarelto 15 mg, Rotaritmil 200 mg, Torasemide 10 mg166 cm 68 kgIschemic heart disease:stable angina pectoris, Functional class, grade III. Diffuse and post-infarction cardiosclerosis (2018). Coronoventriculography and stenting of the coronary arteries. 2DES. Proline aneurysm. Relative insufficiency of the mitral valve and tricuspid valve, persistent atrial fibrillation. Heart failure, grade IIA, Functional class, grade III with preserved systolic function of the left ventricle.High degree myopia of the left eye 01/01/2018, Chronic prostatitis 01/01/2012, Benign prostatic hyperplasia 01/01/2015, Discirculatory encephalopathy with asthenic neurotic syndrome 01/01/2018, Chronic gastroduodenitis 01/01/2018
Nolpaza (Pantoprazolum) 04/08/2019, Medopram 08/04/2019
Atrial fibrillation with heart rate of 133-60, normal electrical axis of the heart. Left ventricular hypertrophy. Scars in the anterior-septal-upper region of the left ventricle.
8-Apr-19
BBS0000-A0900108743090319DDHeart FailureSerum1.0015.00$200.0051 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart120/80Sinus rhythm, frequent supraventricular extrasystole, heart rate - 92 beats per minute, ST-segment elevation in anterior lateral region left ventricle.Laboratory resultsC-reactive protein (CRP) -62.83 mg / l; Creatine Kinase-MB (CPK-MB) -11 U/l; Troponin I <0.1 ng/ml; NT-proBNP-105.5 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownDofamine 5 mg, Ramipril 5 mg, Rosuvastatin 20 mg, Bisoprolol 2.5 mg, Cordarone (Amiodarone) 600 mg, Eplerenone 25 mg, Lospirin (Acetylsalicylic acid) 75 mg185 cm 120 kgIschemic heart disease: progressive angina (08/26/2019), complicated by acute heart failure (Killip - IV 08/26/2019). Coronaroventriculography (08/26/2019) - intact coronary arteries, hydropericardium, left ventricular failure, tricuspid insufficiency grade 1, acute supraventricular tachycardia. Essential hypertension, stage II grade III. Heart failure, grade II A functional class II (NYHA).Chronic pyelonephritis of the left kidney 01/01/1986
N/A
Atrial fibrillation, heart rate - 150-50 beats per minute. Сompared to ECG from 08/30/2019 atrial fibrillation appeared.
31-Aug-19
Contractility left ventricle remained constant. Asymmetric hypertrophy left ventricle. Increase in the cavities of both atria. Aortic compaction, mitral valve, aortic valve. Signs of pulmonary hypertension 0-1 stage. A small amount of fluid in the pericardial cavity.
26-Aug-19
08/27/2019 - Troponin T - 0.05 ng/ml; 08/29/2019 - Troponin T - 0.05 ng/ml
27-Aug-19
BBS0000-A0900108746082719DDHeart FailureSerum1.0010.00$200.0056 YMaleNon-Hispanic<-70C27-Aug-19ECG | Heart160/100Aorta-3.1; Aortic valve-normal; Left atrium-3.5; Final diastolic size of the left ventricle-4.6; Right ventricle-2.7; EF-40%Laboratory resultsC-reactive protein (CRP) -1.46 mg/l; Creatine Kinase-MB (CPK-MB) -24 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 667 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownSpironolactonum 50 mg, Digoxinum 0.25 mg, Warfarinum 2.5 mg, Ramipril 10 mg, Clivas (Rosuvastatin) 10 mg, Nitrosorbidum ( Isosorbidi dinitras) 40 mg187 cm 90 kgIchemic heart disease; Exertional angina, stage III; Cardiosclerosis; Persistent atrial fibrillation; Essential hypertension, grade II; Heart failure, grade IIA with reduced ejection fraction of the left ventricular. Functional class III (NYHA).Chronik obstructive pulmonary disease, stage III, group C 01/01/2017, Discirculatory encephalopathy 01/01/2006
Simbicort Turbuhaler (Micronized budesonide, Formoterol fumarate dihydrate) 01/01/2017, 01/01/2019, Berodual (Fenoterol and ipratropium bromide) 01/01/2017, 01/01/2019
Atrial fibrillation, normo-tachyaritis of the ventricles
19-Aug-19
BBS0000-A0900108858082919DDHeart FailureSerum1.0015.00$200.0072 YFemaleNon-Hispanic<-70C29-Aug-19ECG | Heart110/6008/19/2019 - 0.3 ng/ml (N 0-0.3); 08/23/2019 - 10.16ng/ml; 08/24/2019 - 8.22 ng/ml; 08/27/2019 - 4.37 ng/ml.Laboratory resultsC-reactive protein (CRP) -16.54 mg/l; Creatine Kinase-MB (CPK-MB) - 8 U/l; Troponin I 1.45 ng/ml; NT-proBNP - 2566 pg/ml29-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCorvitin (Quercetin) 0.5 g, Antares 4.0 ml, Arixtra 2.5 mg, Concor 2.5 mg, Cardiomagnyl 75 mg, Roksera 20 mg167 cm 78 kgIschemic heart disease:unstable angina (8/18/2019) with acute heart attack (8/23/2019). Pacemaker (1/1/2011). Heart failure, grade IIA, Functional class, grade III (NYHA) with preserving the ejection fraction.Arterial hypertension 01/01/2010, Cardiac pacemaker 01/01/2011, Diabetes mellitus, type II 01/01/2018
Diabeton (Gliclazidum), Cardiomagnyl, Arixtra, Soritmik, Corvitin (Quercetin)
The sinus rhythm is correct. Pacemaker does not work. Signs of an enlarged left ventricle.
20-Aug-19
Systolic function is reduced. Dilatation of the left atrium. Aortic valve stenosis, stage I. Mitrile valve insufficiency, stage I. Left ventricular hypertrophy.
20-Aug-19
BBS0000-A0900108859083019DDHeart FailureSerum1.0015.00$200.0054 YFemaleNon-Hispanic<-70C30-Aug-19ECG | Heart105/70Ischemia of the posterior lateral portion of the left atriumLaboratory resultsC-reactive protein (CRP) -4.57 mg/l; Creatine Kinase-MB (CPK-MB) - 7 U/l; Troponin I 0.137 ng/ml; NT-proBNP - 1071 pg/ml30-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownSydnopharm (Molsidominum) 4 mg, Cardiomagnyl (Acetylsalicylic acid) 75 mg, Clopidogrel 75 mg, Rosuvastatin 20 mg, Ramizez (Ramipril) 2.5 mg, Flenoks 0.6 ml168 cm 58 kgIschemic heart disease. Progressive angina (unstable 8/12/2019); Stenotic coronary sclerosis (many vascular lesions); Heart failure, grade IIA; Functional class, grade II (NYHA).Primary hypothyroidism
Euthyrox (Levothyroxine sodium) 08/13/2019
Cameras-N; EF-60%
12-Aug-19
Many vascular lesions.
22-Aug-19
BBS0000-A0900108864082219DDHeart FailureSerum1.0013.00$200.0048 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart115/80Sinus rhythm, horizontal electric axis of heart, myocardial infarction with Q wave.Laboratory resultsC-reactive protein (CRP) - 5.02 mg/l; Creatine Kinase-MB (CPK-MB) - 12 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 666.1 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBrilinta (Ticagrelor) 90 mg 2 times per day, Enoxaparin 0.8 ml 2 times per day, Acetylsalicylic acid 75 mg, Bisoprolol 2.5 mg, Eplerenone 50 mg168 cm 68 kgIschemic heart disease with Q wave. Myocardial infarction of the posterior wall of the left ventricle. Stenting of the right coronary artery. Regurgitation of the mitral valve, aortic valve, tricuspid valve, stage I. Heart failure, grade IIA, , functional class, grade II (NYHA).N/A
N/A
The sinus rhythm is correct. Myocardial infarction. Adequate load response.
20-Aug-19
Reduced contractility of the left ventricular myocardium, heart cavities are not enlarged. Regurgitation of the mitral valve, aortic valve, tricuspid valve, stage I. Aortocardiosclerosis of the posterior wall of the left ventricle.
8-Aug-19
08/11/2019 - Tropopnin T - 1.960 ng/ml; 08/09/2019 - Troponin T - 1.799 ng/ml
11-Aug-19
BBS0000-A0900108865090219DDHeart FailureSerum1.0011.00$200.0048 YMaleNon-Hispanic<-70C02-Sep-19ECG | Heart140/90Atrial fibrillation with a heart rate of 70-90 beatsLaboratory resultsC-reactive protein (CRP) -0.57 mg/l; Creatine Kinase-MB (CPK-MB) -13 U/l; Troponin I <0.1 ng/ml; NT-proBNP-464 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownWarfarinum 6.25 mg, Clivas (Rosuvastatin) 10 mg, Nebivolol 2.5 mg, Kombisart 160/10 mg192 cm 127 kgIschemic heart disease: cardiosclerosis. Permanent form of atrial fibrillation. Essential hypertension, grade II, stage II. Heart failure, grade IIA. Functional class III (NYHA).N/A
N/A
Left atrium-V-70 cm^3; The back wall of the left ventricle-1.2; Interventricular septum-1.3-1.3 g; EF-58%.
28-Aug-19
BBS0000-A0900109092082219DDHeart FailureSerum1.0013.00$200.0056 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart120/80Heart rate 110-170. Atrial fibrillation, increased load on the right. Diffuse repolarization disordersLaboratory resultsС-reactive protein (CRP)-6.81 mg/l; Creatine Kinase-MB (CPK-MB)- 19 U/l; Troponin I-0.88 ng/ml; NT-proBNP- 7658 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCordarone (Amiodarone) 200 mg, Arixtra (Fondaparinux sodium) 2.5 mg, Koriol 6.25 mg, Renial 50 mg, Torasemide 10 mg170 cm 68 kgIschemic heart disease: diffuse cardiosclerosis. Relative mitral valve insufficiency, stage II. Persistent tachyform of atrial fibrillation. Heart failure, grade IIB, Functional class, grade IV (NYHA), with reduced lunge fraction.Сhronic obstructive pulmonary disease, group C; GOLD III, stage of non-infectious inflammation
Simbicort Turbuhaler (Micronized budesonide, Formoterol fumarate dihydrate) 08/21/2019
End-diastolic size of the left ventricle 6.1; End systolic size 5.2; end-diastolic volume 187; final systolic volume 127. Significantly reduced left ventricular myocardial contractility. The atrial cavity is enlarged.
21-Aug-19
BBS0000-A0900109093091119DDHeart FailureSerum1.0014.00$200.0060 YMaleNon-Hispanic<-70C11-Sep-19ECG | Heart120/80Laboratory resultsC-reactive protein (CRP) - 20.07 mg/l; Creatine Kinase - MB (CPK-MB) - 22 U/l; Troponin I - 0.501 ng/ml; NT-proBNP - 6526 pg/ml11-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCordarone (Amiodarone) 200 mg, Warfarinum 2.5 mg, Renial 50 mg, Torasemide 8 mg, Tivortin (Arginine hydrochloride) 100 ml, Vazoklin 20 mg170 cm 70 kgIschemic heart disease: diffuse cardiosclerosis. Mitral valve and triskupid valve insufficiency, stage II. Heart failure, grade IIA-B, Functional class, grade III (NYHA) with reduced ejection fraction.Essential hypertension, grade II, stage III Сhronic obstructive pulmonary disease, stage II
Aerofillin, Mutsitus, Bisoprolol, Ramipril
Atrial fibrillation with a heart rate of 80/180 beats per minute. Hypertrophy of both ventricles. Diffuse left ventricular myocardial ischemia.
4-Sep-19
BBS0000-A0900109172090519DDHeart FailureSerum1.0011.00$200.0081 YFemaleNon-Hispanic<-70C05-Sep-19ECG | Heart140/80Laboratory resultsC-reactive protein (CRP) - 9.58 mg/l; Creatine Kinase - MB (CPK-MB) - 6 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 1440 pg/ml5-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownN/A170 cm 80 kgIschemic heart disease: cardiosclerosis. Heart failure, grade I. Functional class, grade II (NYHA).N/A
N/A
BBS0000-A0900109173083019DDHeart FailureSerum1.0015.00$200.0070 YFemaleNon-Hispanic<-70C30-Aug-19ECG | Heart160/90Sinus rhythm is regular. Deviation of the electrical axis of the heart to the left. Moderate systolic load on the left ventricle.Laboratory resultsC-reactive protein (CRP) -0.8 mg/l; Creatine Kinase-MB (CPK-MB) - 10 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 1297 pg/ml30-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownTorasemide 10 mg, Carvedilol 25 mg, Perindopril 10 mg170 cm 91 kgIschemic heart disease: exertional angina, functional class 3; cardiosclerosis. Aortic defect with a predominance of stenosis of the III degree. Mitral valve insufficiency, arterial hypertension. Heart failure IIA with stored ejection fraction, functional class III - IV (NYHA).Ischemic heart disease 01/01/2010, Aortic defect with a predominance of stenosis 01/01/2017, Arterial hypertension 01/01/2010, Psoriasis 01/01/1980
Vasopro (Mildronate) 08/29/2019, Clivas (Rosuvastatin) 08/29/2019, Kardioarginin 08/29/2019
Systolic function persists. Dilatation of the left atrium. Hypertrophy of the walls of the left ventricle. Aortic valve stenosis, grade 2.
30-Aug-19
BBS0000-A0900109222090319DDHeart FailureSerum1.0012.00$200.0080 YFemaleNon-Hispanic<-70C03-Sep-19ECG | Heart120/70Mitral valve-N; Moderate fibrosis; Wall of the left ventricle-N; EF-66%; Aortic valve-N; Moderate fibrosis; Aorta-N; Left atrium-N; Right atrium-N; Cavities of the heart are not enlarged. The ejection fraction is saved.Laboratory resultsC-reactive protein (CRP) -5.6 mg / l; Creatine Kinase - MB (CPK-MB) -15 U/l; Troponin I <0.1ng / ml; NT-proBNP-417.20 pg / ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCarvedilol 25 mg172 cm 68 kgIschemic heart disease:cardiosclerosis. Heart failure, grade I. Functional class II (NYHA).N/A
N/A
BBS0000-A0900109224091019DDHeart FailureSerum1.0014.00$200.0053 YFemaleNon-Hispanic<-70C10-Sep-19ECG | Heart140/80Laboratory resultsC-reactive protein (CRP) - 20.44 mg/l; Creatine Kinase - MB (CPK-MB) - 7 U/l; Troponin I - <0.1 ng/ml; NT-proBNP - 122.5 pg/ml10-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCardiomagnyl (Acetylsalicylicum asid) 75 mg172 cm 84 kgIschemic heart disease: cardiosclerosis. Heart failure, grade I. Functional class, grade II (NYHA).N/A
N/A
BBS0000-A0900109255082219DDHeart FailureSerum1.0015.00$200.0051 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart160/80Scars of the posterior wall are sealed. History of myocardial infarction. Signs of strain on both ventricles. Sinus rhythm. Deviation of the electrical axis of the heart to the left.Laboratory resultsC-reactive protein (CRP) -0.82 mg/l; Creatine Kinase-MB (CPK-MB) -14 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 96.73 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownAspirin cardio (Acetylsalicylic acid) 75 mg, Klosart (Losartan) 50 mg, Semlopin 10 mg, Bisoprolol 5 mg173 cm 71 kgIschemic heart disease: diffuse and post-infarction cardiosclerosis (2016), aortic angina, relative insufficiency of the triskupid valve. Heart failure, grade II functional class II (NYHA).Podagra 01/01/2017
Allopurinol 01/01/2017
Left ventricular myocardial contractility is normal. Left ventricular hypertrophy with type I diastolic dysfunction. Slightly enlarged cavity of the heart. Compaction of the aorta. Signs of stenosis of the aortic orifice of I degree, relative insufficiency of the triskupid valve of I degree.
14-Aug-19
BBS0000-A0900109256082919DDHeart FailureSerum1.0015.00$200.0077 YMaleNon-Hispanic<-70C29-Aug-19ECG | Heart120/80Congestion in the lungs. The roots are dilated, stagnant. On the right, up to 6 ribs darken due to free fluid. Aortic sclerosis. Condition after heart surgery.Laboratory resultsC-reactive protein (CRP) -4.42 mg/l; Creatine Kinase-MB (CPK-MB) - 15 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 530.4 pg/ml29-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownEplerenone 25-50 mg, Torasemide 10 mg, Nebivolol 2.5 mg, Ramipril 10 mg173 cm 84 kgIschemic heart disease:angina pectoris, Functional class, grade II. Coronary Aortic Bypass Surgery-II (1/16/2015). Aortic malformation with a predominance of stenosis, stage I-II. Mitral valve insufficiency, stage II, Tricuspid valve insufficiency, stage II. Heart failure, grade IIA, Functional class, grade II-III (NYHA) with preserving the ejection fraction 58%. Arterial hypertension, stage III. (Acute cerebral impairment - 2013).Arterial hypertension 01/01/2000, Acute cerebrovascular accident 01/01/2013, Ischemic heart disease:Coronary artery bypass grafting - 2 01/26/2015, Chronic anemia 08/01/2019, Diabetes mellitus, type II 01/01/2013
Amaryl (Glimepiride) 01/01/2013, Ksarelto 08/01/2019, Atorvastatin 08/01/2019
Systolic function is reduced. Dilation of the left atrium, hypertrophy of the right ventricle, walls of the left ventricle. Mitral valve insufficiency, stage II. Tricuspid valve insufficiency, stage I. Pulmonary aortic valve insufficiency, stage I. Pulmonary hypertension.
22-Aug-19
Troponin I 0.2 (N 0-0.5 mg/l)
28-Aug-19
BBS0000-A0900109257082219DDHeart FailureSerum1.0015.00$200.0071 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart120/80Sinus rhythm, heart rate 92 beats / min. Complete blockade of the left bundle branch block. Scars in the anterior wall of the left ventricle.Laboratory resultsС-reactive protein (CRP) -7.46 mg/l; Creatine Kinase-MB (CPK-MB) - 10 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 5535 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCorvitin (Quercetin) 0.5 g, Torasemide 20 mg, Clopidogrelum 75 mg, Valsartan 160 mg, Amlodipin (Amlodipinum) 10 mg173 cm 85 kgIschemic heart disease: stable exertional angina. Functional class, grade II. Postinfarction cardiosclerosis. Complete blockade of the left bundle branch block. Heart failure, grade IIA; Functional class, grade III (NYHA). Essential hypertension, grade III, stage III.Diabetes mellitus, type II 01/01/1986, Atherosclerosis obliterans of the lower extremities 01/01/2015, Chronic kidney disease, stage II: diabetic nephropathy. Chronic kidney disease, grade I 01/01/2015
Insuman Comb 25 GT (Insulin human) 01/01/2008, Atorvaststinum 01/01/2015
The ejection fraction is 45%. Signs of cicatricial changes in the left ventricle. Hypertrophy of the left ventricle with type II diastolic dysfunction, myrtle valve insufficiency, grade I-II
16-Aug-19
BBS0000-A0900109258090219DDHeart FailureSerum1.0014.00$200.0080 YMaleNon-Hispanic<-70C02-Sep-19ECG | Heart145/90Sinus rhythm, heart rate - 85 beats per minute. Electrical axis of the heart is deflected to the left. Blockage of the anterior branch of the left atrium band His. Load on both ventricles. CicatricIal changes with N - V6.Laboratory resultsC-reactive protein (CRP) -1.36 mg/l; Creatine Kinase-MB (CPK-MB) - 6 U/l; Troponin I <0.1 ng/ml; NT-proBNP- 40.33 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownTrinomiya 100/20/10 mg, Torasemide 10 mg, Cardiket (Isosorbidi dinitros) 20 mg174 cm 42 kgIschemic heart disease: stable exertional angina functional class III. Postinfarction cardiosclerosis, heart failure grade II A. Functional class III (NYHA) with preserved ejection fraction.Obliterative atherosclerosis vessels of lower limbs, grade II Essential hypertension (great risk) 01/01/2018
N/A
Left ventricular end-diastolic dimension - 5.1, left ventricular end-systolic dimension - 3.7, end-diastolic volume - 125, end-systolic volume - 58, stroke volume - 66, ejection fraction - 53%, interventricular septum - 1.2, left ventricle posterior wall - 1.2, left atrium - 4.0, left ventricle - 3.0.
2-Sep-19
BBS0000-A0900109311090219DDHeart FailureSerum1.0013.00$200.0057 YMaleNon-Hispanic<-70C02-Sep-19ECG | Heart140/95Laboratory resultsC-reactive protein (CRP) -0.77 mg/l; Creatine Kinase-MB (CPK-MB) -11 U/l; Troponin I 0.176 ng/ml; NT-proBNP-469.90 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCordarone (Amiodarone) 200 mg, Estulic 1 mg, Vazoklin 20 mg, Magnikor (Acetylsalicylic acid) 75 mg, Aterokard 75 mg, Renial 50 mg175 cm 102 kgIschemic heart disease: diffuse cardiosclerosis. Relative insufficiency of the mitral valve and tricuspid valve, stage II-III. Permanent tachyform of atrial fibrillation. Heart failure, grade IIAB, Functional class, grade IV (NYHA).Essential hypertension 01/01/2004, Lacunar disease 01/01/2016, Diffuse goiter, stage I 01/01/2016, Diabetes, light form 04/18/2018
N/A
Atrial fibrillation with a heart rate of 120 strokes. Left ventricular hypertrophy.
30-Aug-19
BBS0000-A0900109312082819DDHeart FailureSerum1.0013.00$200.0047 YFemaleNon-Hispanic<-70C28-Aug-19ECG | Heart130/80Aorta-3.0; Aortic valve-normal; Left atrium-4.2; Mitral valve-normal; Posterior wall-1.0; Ventricular septum-1.3-1.4 moderate hypokinesis; Left ventricle-4.2; Right ventricle-3.5. Pressure in the left artery-42; EF-51%.Laboratory resultsC-reactive protein (CRP) -6.57 mg/l; Creatine Kinase-MB (CPK-MB) -12 U/l; Troponin I <0.1 ng/ml; NT-proBNP-2455 pg/ml28-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownWarfarinum 10 mg, Diocor (Valsartan + Hidrochlorothiazide) 40 mg, Diakordin (Diltiazemum) 30 mg, Verospiron (Spironolactone) 50 mg, Triductan (Trimetazidine) MB 35 mg, Trifas (Torasemide ) 10 mg175 cm 200 kgIschemic heart disease: cardiosclerosis. Thromboembolism of pulmonary artery. Heart failure, grade IIB. Functional class IV (NYHA).Diabetes mellitus 01/01/2000, Excessive obesity with hypoventilation of the lungs. Pulmonary insufficiency, stage II-III 01/01/2000
N/A
Partial right bundle branch block. Signs of left ventricular hypertrophy and right ventricular hypertrophy with its overload.
23-Aug-19
BBS0000-A0900109313090319DDHeart FailureSerum1.0015.00$200.0092 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart120/60Rhythm sinus regular, delayed conduction, type I. Incomplete blockade of the left bundle branch block. Fibrous changes in the anterior-membranous-upper region.Laboratory resultsC-reactive protein (CRP) - 5.97 mg/l; Creatine Kinase-MB (CPK-MB) - 17 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 107.7 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownNebivolol 2.5 mg, Torasemide 10 mg 2 times per week, Amiodarone 100 mg, Aspirin cardio (Acetylsalicylic acid) 100 mg175 cm 91 kgIschemic heart disease: cardiosclerosis with permanent mould. Atrial fibrillation, grade III, stage I, risk IV. Heart failure, grade IIA. Functional class, grade III (NYHA).Chronic pancreatitis, gastroduodenitis (recurrent) 01/01/1990, Chronic gastritis, cholecystopancreatitis (recurrent) 01/01/1990, Ischemic heart disease with arterial hypertension; postinfarction cardiosclerosis 01/01/1967
Pantasun (Pantоprazole) 04/17/2019, 04/22/2019, Kreazim 04/17/2019, 04/22/2019, Gaviscon (Calcium carbonate, Sodium alginate, Sodium hydrocarbonate), 04/17/2019, 04/22/2019
Additional chord in the left ventricle. Dilation of both chambers of the heart. Hypertrophy of the walls of the left ventricle. Combined aortic vada, stage I-II.
3-Sep-19
BBS0000-A0900109314090319DDHeart FailureSerum1.0014.00$200.0059 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart160/100Sinus rhythm 54 beats per second. Scars of the back wall. Left ventricular hypertrophy. Blockade of the anterior left leg of the bundle of Hisa. Ventricular extrasystoleLaboratory resultsC-reactive protein (CRP) - 6.44 mg/l; Creatine Kinase - MB (CPK-MB) - 12 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 250 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBisoprolol 5 mg, Verospiron (Spironolactone) 50 mg, Magnikor (Acetylsalicylic acid) 75 mg, Bi-Prestarium (Perindoprilum, Amlodipinum) 10/5 mg,175 cm 95 kgIschemic heart disease: diffuse and post-infarction cardiosclerosis (2003). Essential hypertension, grade III, stage III, high risk. Heart failure grade IIA, Functional class III (NYHA).Gout 01/01/2016
Allopurinol 01/01/2016
Left ventricular myocardial hypertrophy. Systolic and diastolic function within normal limits. Enlarged left atrium. Mitral and triskupal valve regeneration, stage I.
3-Sep-19
BBS0000-A0900109391090419DDHeart FailureSerum1.0013.00$200.0059 YMaleNon-Hispanic<-70C04-Sep-19ECG | Heart140/80Atrial fibrillation. Cicatricial changes in the posterior wall of the left ventricle, moderate diffuse changes in the myocardium.Laboratory resultsC-reactive protein (CRP) - 1.15 mg/l; Creatine Kinase - MB (CPK-MB) - 15 U/l; Troponin I <0.144 ng/ml; NT-proBNP - 1089 pg/ml4-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownWarfarinum 5 mg, Valodip (Amlodipine, Valsartan) 160/5 mg, Atorvastatin 20 mg, Metonat 102.5 ml176 cm 100 kgIschemic heart disease: stable exertional angina, functional class, grade III. Postinfarction cardiosclerosis (2009). Mitral valve insufficiency and triskupid, stage II. Binodal disease. Persistent atrial fibrillation. Heart failure, grade IIA with increased ejection fraction of the left ventricle. Essential hypertension, grade III. Functional class, grade III (NYHA).
Grade IIA with increased ejection fraction of the left ventricle. Essential hypertension, grade III.
Dyscirculatory encephalopathy, grade II atherosclerotic-hypertrophic insufficiency 01/01/2009
Neurotropine (Mexidol) 08/27/2019, 09/04/2019
Atrial cavities are enlarged, left ventricular myocardial hypertrophy. Systolic function is satisfactory. Relative mitral valve and triskupid insufficiency, stage II. Aortic atherosclerosis
28-Aug-19
BBS0000-A0900109392083019DDHeart FailureSerum1.0011.00$200.0051 YMaleNon-Hispanic<-70C30-Aug-19ECG | Heart170/110Ectopic rhythm, atrial fibrillation, left ventricular hypertrophy, incomplete blockade of the left bundle branch block.Laboratory resultsC-reactive protein (CRP) -2.84 mg/l; Creatine Kinase-MB (CPK-MB) -12 U/l; Troponin I 0.784 ng/ml; NT-proBNP-3163 pg/ml30-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownTriplixam (Perindopril arginine+amlodipine + indapamide) 10/2.5/10 mg, Spironolactonum 25 mg, Bisoprolol 5 mg, Clivas (Rosuvastatin) 10 mg, Plavix (Clopidogrel) 75 mg176 cm 110 kgIschemic heart disease:cardiosclerosis. Permanent form of atrial fibrillation. Essential hypertension, grade II, stage II. Heart failure, grade II. Functional class, grade III (NYHA).Ð?besity, grade II 07/02/2015
N/A
Aorta-3.6; aortic valve-normal; left atrium-7.6 (increased); walls-1.6-3.0; thickness of the interventricular septum-1.7-1.8; final diastolic size of the left ventricle-5.2; pulmonary hypertension-(-); EF-58.
22-Aug-19
Retinal vascular angiopathy
22-Aug-19
Kidneys: rights - 112 * 48 left-109 * 51 parenchyma 15 and 19 cm thick. Smooth muscle cells are not expanded. Renal hypertrophy.
29-Aug-19
BBS0000-A0900109394082219DDHeart FailureSerum1.0013.00$200.0063 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart125/85Sinus rhythm, heart rate of 120 beats per minute. Violation of processes of repolarization in the back wall of the left ventricle.Laboratory resultsC-reactive protein (CRP) - 10.8 mg/l; Creatine Kinase-MB (CPK-MB) - 13 U/l; Troponin I <0.1 ng/ml; HT-proBNP- 25.35 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownRenial 50 mg, Norvasc (Amlodipinum) 5 mg, Trinomiya 100/20/10 mg, Bisoprolol 5 mg, Torasemide 40 mg176 cm 144 kgIschemic heart disease: diffuse cardiosclerosis, Functional class, grade III from stored ejection volume. Essential hypertension, grade III high risk. Heart failure, grade IIA. Mitral valve insufficiency II, tricuspid valve III. Functional class III (NYHA).Сhronic obstructive pulmonary disease, group C, the period of non-infectious exacerbation 01/01/2015
Renial 07/02/2019, Norvasc (Amlodipinum) 08/20/2019, Trinomiya 07/02/2019, Bisoprolol 07/02/2019, Torasemide 08/20/2019
The final diastolic size of the left ventricle 6.1; final systolic size of the left ventricle 4.3; final diastolic volume of the left ventricle 184; final systolic volume of the left ventricle 0.3; left ventricular ejection volume 55; left atrium 4.6; right ventricle 2.6. Left ventricular myocardial hypertrophy with grade I diastolic dysfunction, systolic function is not impaired. Enlarged atrial cavities, aortic atherosclerosis, seal aortic valve, mitral valve.
20-Aug-19
BBS0000-A0900109395090319DDHeart FailureSerum1.0011.00$200.0052 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart120/70Q-S, V-V3, elevation S-T, V2-V5, negative T V2-V6Laboratory resultsC-reactive protein (CRP) - 2.68 mg/l; Creatine Kinase-MB (CPK-MB) - 8 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 2190 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBrilinta (Ticagrelor) 90 mg 2 times per day, Agrel (Clopidogrelum) 75 mg, Concor (Bisoprololum) 2.5 mg 1/2 times per day, Tricard (Trimetazidinum) 5 mg176 cm 87 kgIschemic heart disease. Myocardial infarction. Heart failure, grade IIA. Functional class III (NYHA).Gastric ulcer 01/01/1999
Pantasun (Pantоprazole) 08/21/2019
Hypokinesis of the anterior segment
3-Sep-19
Сreatine phosphokinase 62.8 U/L
21-Aug-19
Occlusion of the anterior interventricular artery
21-Aug-19
BBS0000-A0900109474082719DDHeart FailureSerum1.0015.00$200.0055 YMaleNon-Hispanic<-70C27-Aug-19ECG | Heart120/80Laboratory resultsC-reactive protein (CRP) -4.57 mg/l; Creatine Kinase-MB (CPK-MB) - 13 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 1842 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCordarone (Amiodarone) 200 mg, Inspra (Eplerenonum) 50 mg, Torasemide 20 mg, Warfarinum 7.5 mg, Simvastatin 20 mg, Kontrolok 40 mg176 cm 95 kgIschemic heart disease:Exertional angina stable, Functional class III. Postinfarction cardiosclerosis. Mitral valve repair and de Vega tricuspid insufficiency. Frequent ventricular extrasystole. Instant hypertension. Heart failure, grade IIB, Functional class, grade IV (NYHA) with reduced systolic function of the left ventricle.Chronic duodenitis 01/01/2017, Fatty liver 01/01/2018, Urolithiasis disease. Microlites of both kidneys. 01/01/2017
Ursolisin
Sinus rhythm, heart rate 100. Ventricular extrasystole. Diffuse disorders of left ventricular repolarization.
25-Jul-19
BBS0000-A0900109476090219DDHeart FailureSerum1.0015.00$200.0053 YMaleNon-Hispanic<-70C02-Sep-19ECG | HeartU/AEctopic rhythm, atrial fibrillation, ventricular tachyarrhythmia, ventricular extrasystole. Left ventricular hypertrophy.Laboratory resultsC-reactive protein (CRP) -7.51 mg /l; Creatine Kinase-MB (CPK-MB) -12 U/l; Troponin I <0.1 ng/ml; NT-proBNP-1737 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownTrifas (Torasemide ) 5 mg, Digoxinum 0.25 mg, Cordarone (Amiodarone) 100 mg, Aspirin cardio (Acetylsalicylic acid) 100 mg, Spironolactonum 25 mg, Furosemide 4.0 ml intravenously178 cm 120 kgIschemic heart disease:cardiosclerosis. Dilation of the heart chambers. Permanent form of atrial fibrillation. Essential hypertension, grade II, stage II. Heart failure, grade IIB, Functional class, grade III (NYHA).Mixed goiter, hyperthyroidism N/A, Alimentary constitutional obesity N/A, Chronic hepatitis N/A, Chronic pancreatitis
N/A
Enlarged left atrium, right chambers, heart, pressure in the left atrium, pericardium. SE-34.
28-Aug-19
The heart is expanded in cross section. Bilateral congestive pneumonia.
2-Sep-19
Significantly increased (ascites), edema
29-Aug-19
BBS0000-A0900109477082219DDHeart FailureSerum1.0015.00$200.0052 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart140/100QRS voltage is reduced. Ectopic atrial rhythm. Heart rate - 67 beats per minute. The horizontal position of the electrical axis of the heart. The load on the right ventricle, repolarization processes are disturbed.Laboratory resultsC-reactive protein (CRP) -3.01 mg/l; Creatine Kinase-MB (CPK-MB) - 10 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 41.07 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBisoprolol (Bisoprololum) 5 mg, Clopidogrel 75 mg, Co-Amlessa ( Perindopril+Indapamide+Amlodipine) 8/2.5/5 mg,178 cm 75 kgCoronary heart disease: stable angina pectoris. Permanent atrial fibrillation. Diffuse cardiosclerosis (2016). Cardiovascular risk (2016). Stenting of the anterior interventricular branch of the left coronary artery - 1 BMS, of the right coronary artery - 1 BMS. Heart failure, grade II functional class II (NYHA)Podagra, coxarthrosis 01/01/2016
Adenuric (Febuxostatum) 01/01/2017, Naklofen (Diclofenac Sodium) 01/01/2018
Left ventricular myocardial contractility is normal. Left ventricular hypertrophy with type I diastolic dysfunction. Aortocardiosclerosis, dilated aorta ascending part. The cavity of the left atrium is enlarged. Mitral valve insufficiency of I degree, relative insufficiency of triskupidal valve of I degree.
15-Aug-19
BBS0000-A0900109542090419DDHeart FailureSerum1.0015.00$200.0070 YFemaleNon-Hispanic<-70C04-Sep-19ECG | Heart150/100Heart rate not increased. Left ventricular myocardial contractility is not impaired. Mitral valve and tricuspid valve insufficiency, stage II.Laboratory resultsC-reactive protein (CRP) -1.15 mg/l; Creatine Kinase-MB (CPK-MB) -11 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 569.8 pg/ml4-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownDifors (Valsartan + Amlodipine ) 160/5 mg, Verospiron (Spironolactone) 25 mg, Bisoprolol (Bisoprololum) 2.5 mg, Aspirin cardio (Acetylsalicylic acid) 100 mg, Rosart (Rosuvastatinum) 20 mg156 cm 78 kgIschemic heart disease: diffuse cardiosclerosis. Mitral valve and triskupid valve insufficiency. Hypertensive disease stage II, grade 3, high risk. Heart failure, grade I. Functional class, grade II (NYHA).Deforming osteoarthrosis 01/01/2015
Dicloberl (Diclofenac) 01/01/2016
Sinus rhythm; Deviation of the electrical axis of the heart to the left; Violation of the processes of repolarization of the posterior wall of the left ventricle.
28-Aug-19
BBS0000-A0900109544090319DDHeart FailureSerum1.0013.00$200.0045 YFemaleNon-Hispanic<-70C03-Sep-19ECG | Heart125/80Sinus rhythm, heart rate 80 beats per minute. The electrical axis of the heart is deflected to the left. Focal changes in the anterior region of the left ventricle.Laboratory resultsC-reactive protein (CRP) - 6.75 mg/l; Creatine Kinase - MB (CPK-MB) - 7 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 42.94 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCiticoline 1000 mg160 cm 110 kgIschemic heart disease: stable exertional angina, functional class, grade III. Postinfarction cardiosclerosis. Stenting of the right interventricular septum. Heart failure, grade IIA, functional class, grade III (NYHA). Essential hypertension, grade III, risk IV.Residual effects of myocardial infarction by ischemic type 10/06/2017, Dyscirculatory encephalopathy, grade III atherosclerotic-hypertrophic genesis 10/06/2017, Nutritional obesity 01/01/2016
Citicoline 08/27/2019, 09/02/2019, Clopidogrel 10/06/2017, Atorvastatin 10/06/2017
Left ventricular myocardial hypertrophy. Left ventricular contractility is not impaired. Valve function satisfactory
28-Aug-19
BBS0000-A0900109545082319DDHeart FailureSerum1.0011.00$200.0083 YMaleNon-Hispanic<-70C23-Aug-19ECG | Heart120/80Sinus rhythm AV blockade, stage I; Cicatricial changes changes of the anterior septum: posterior wall of the left ventricle.Laboratory resultsC-reactive protein (CRP) -199.23 mg/l; Creatine Kinase-MB (CPK-MB) -19 U/l; Troponin I <0.1 ng/ml; NT-proBNP-18448 pg/ml23-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBrilinta (Ticagrelor) 90 mg, Pantasun (Pantоprazole) 40 mg, Perindoprilum 4 mg, Atorvacor (Atorvastatinum) 20 mg, Sydnopharm (Molsidominum) 2 mg, Verospiron (Spironolactone) 50 mg160 cm 64 kgIschemic heart disease. Exertional angina stable, Functional class, grade III. Postinfarction cardiosclerosis (2004, 2019). Stenotic coronarosclerosis. Recurrent cardiac asthma. Essential hypertension, grade II. Heart failure, grade IIA. Functional class III (NYHA).Discirculatory encephalopathy with modified violations 06/14/2013
N/A
Aorta-3.9; Aortic valve-normal; Left atrium-14.2; Vmax.-1.4; Pmax.-7; Interventricular septum-1.2; EF-28-30%
23-Aug-19
BBS0000-A0900109553090319DDHeart FailureSerum1.0015.00$200.0052 YMaleNon-Hispanic<-70C03-Sep-19ECG | Heart116/70Q wave-III, aVF, elevation S-T III, segment depression V1-V2.Laboratory resultsC-reactive protein (CRP) - 1.87 mg/l; Creatine Kinase-MB (CPK-MB) - 11 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 1505 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownDiocor solo (Valsartan) 80 mg, Atorvacor (Atorvastatinum) 40 mg, Brilinta (Ticagrelor) 90 mg, Flenox (Enoxaparinum natrii ) 0.8 ml 2 times per day178 cm 89 kgIschemic heart disease. Right ventricular myocardial infarction. Heart failure IIA. Functional class III (NYHA).Gastric ulcer 01/01/2009, Transient ischemic attack 01/01/2017
Pantasun (Pantоprazole) 08/21/2019
Diffuse hypokinesia of the posterior wall of the right ventricle
4-Sep-19
Troponin I >2000 ng/L; Creatine Kinase-MB (CPK-MB) -298.6 U/l
21-Aug-19
AST-242.4
21-Aug-19
BBS0000-A0900109610083019DDHeart FailureSerum1.0014.00$200.0053 YMaleNon-Hispanic<-70C30-Aug-19ECG | Heart130/90Sinus rhythm. Single supraventricular extrasystoles, diffuse changes in the myocardium.Laboratory resultsC-reactive protein (CRP) - 2.14 mg/l; Creatine Kinase-MB (CPK-MB) - 8 U/l; Troponin I <0.1ng/ml; NT-proBNP - 43.11 pg/ml30-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownEnalapril 10 mg, Torasemide 10 mg180 cm 70 kgMetabolic cardiomyopathy. Transient extrasystole, arrhythmia, heart failure, class I functional degree I-II (NYHA), arterial hypertension, grade II stage 1, left ventricular myocardial hypertrophy. Constantly hyperthyroidism.Arterial hypertension 01/01/2015, Papillary carcinoma of the left side of the thyroid gland (operation) 09/20/2017
Metoprololum 01/01/2017, Euthyrox (Levothyroxine sodium) 01/01/2017
Hypertrophy of the walls of the left ventricle, diastolic dysfunction of the left ventricle. Fibro-sclerotic changes in the valve leaflet of the heart. Dilatation of the left atrium.
19-Aug-17
supraventricular single extrasystoles - 26; single ventricular extrasystoles - 15; other rhythm disturbances are not recorded.
26-Nov-18
BBS0000-A0900109611082819DDHeart FailureSerum1.0015.00$200.0054 YMaleNon-Hispanic<-70C28-Aug-19ECG | Heart130/80There is no data on violation of mitral valve prolapse. Mild neurocirculatory dystonia. Slight tricuspid insufficiency. Ventricular contractility is satisfactory.Laboratory resultsC-reactive protein (CRP) -4 mg/l; Creatine Kinase-MB (CPK-MB) -25 U/l; Troponin I <0.1 ng/ml; NT-proBNP-335.3 pg/ml28-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownWarfarinum 7.5 mg, Verapamil 40 mg, Verospiron (Spironolactone) 50 mg180 cm 79 kgChronic rheumatic heart disease, stage II. Mitral valve prosthesis (2018); Aortic insufficiency, aortic valve. Heart failure, grade II, Functional class, grade II (NYHA).N/A
N/A
Sinus rhythm-normal, the position of the electrical axis of the heart, frequent ventricular extrasystoles, left ventricular hypertrophy.
27-Aug-19
BBS0000-A0900109612090919DDHeart FailureSerum1.0014.00$200.0052 YMaleNon-Hispanic<-70C09-Sep-19ECG | Heart140/80diastolic size of L. ventricle-5.0; systolic size of L. ventricle-3.9; diastolic volume of L. ventricle. diastolic volume of L. ventricle-119; systolic volume of L. ventricle-69; L. ventricular ejection fraction-42; L. atrium-3.6; R. ventricle-2.7.Laboratory resultsC-reactive protein (CRP) - 1.68 mg/l; Creatine Kinase - MB (CPK-MB) - 9 U/l; Troponin I - 0.129 ng/ml; NT-proBNP - 113.9 pg/ml9-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownEpletor 25 mg, Ramizez (Ramipril) 5 mg, Flenoks 0.8 mg, Plavix (Clopidogrel) 75 mg, Lospirin (Acetylsalicylic acid) 75 mg, Roksera 40 mg180 cm 80 kgIschemic heart disease:Acute myocardial infarction of the anterior septum. Diffuse and post-traumatic cardiosclerosis. Heart failure, grade IIA, Functional class, grade III (NYHA) with moderately reduced ejection fraction.Duodenal ulcer 01/01/1987, Rheumatism
Nolpaza (Pantoprazolum)
The sinus rhythm is correct. Heart rate 47 beats per minute. Dynamic changes in anterior myocardial infarction.
3-Sep-19
BBS0000-A0900109613090619DDHeart FailureSerum1.0014.00$200.0053 YMaleNon-Hispanic<-70C06-Sep-19ECG | Heart130/80Aorta-3.6; Aortic valve-N; Left atrium-3.7; Mitral valve-N; The final diastolic size of the left ventricle-4.7; Interventricular septum-0.9-1.0; The back wall of the left ventricle-1.0; EF-57%.Laboratory resultsC-reactive protein (CRP) - 0.92 mg/l; Creatine Kinase - MB (CPK-MB) - 10 U/l; Troponin I - <0.1 ng/ml; NT-proBNP - 80.68 pg/ml6-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownConcor 2.5 mg, Aspirin cardio (Acetylsalicylic acid) 100 mg, Trombonet (Clopidogrelum) 75 mg, Triductan MB (Trimetazidine) 35 mg, Ethacyzin 25 mg180 cm 80 kgIschemic heart disease:cardiosclerosis. Atrial fibrillation. Heart failure grade I. Functional class, grade II (NYHA).Essential hypertension 01/01/2007, Diffuse goiter. Thyrotoxicosis 01/01/2017
Thyrozol (Thiamazole) 01/01/2017, Tireoklin 01/01/2017, Prenesa (Perindoprilum) 01/01/2010
The sinus rhythm is wrong. Heart rate 62 beats per minute. Supraventricular ventricular extrasystole.
5-Sep-19
BBS0000-A0900109614082819DDHeart FailureSerum1.0012.00$200.0051 YMaleNon-Hispanic<-70C28-Aug-19ECG | Heart100/70Aorta-3.3; Left atrium-V-90; Minimal regurgitation (+); End-diastolic volume, left ventricle-220; wall-1.0; right ventricle-2.9; EF-36%Laboratory resultsC-reactive protein (CRP) -6.63 mg/l; Creatine Kinase-MB (CPK-MB) -8 U/l; Troponin I <0.1ng/ml; NT-proBNP-12607 pg/ml28-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownYuperio 50 mg, Spironolactonum 50 mg, Torsid (Torasemide) 10 mg, Koriol 12.5 mg, Ksarelto 20 mg180 cm 85 kgDilated cardiomyopathy. Pulmonary embolism. Heart failure, grade IIA with reduced ejection fraction of left ventricular. Functional class III (NYHA).Thrombophlebitis 01/01/2016, Thyrotoxicosis 01/01/2018
N/A
Complete blockade of the left bundle branch block, ventricular extrasystole.
27-Aug-19
BBS0000-A0900111867090319DDHeart FailureSerum1.0015.00$200.0059 YFemaleNon-Hispanic<-70C03-Sep-19ECG | Heart160/95Sinus rhythm is regular, the electrical axis of the heart is deflected to the left. Blockade of the left bundle branch block.Laboratory resultsC-reactive protein (CRP) -0.58 mg/l; Creatine Kinase-MB (CPK-MB) -15 U/l; Troponin I <0.1 ng/ml; NT-proBNP-124 pg/ml3-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownAmlodipin (Amlodipinum) 10 mg, Torasemide 10 mg, Bisoprolol 5 mg161 cm 68 kgArterial hypertension II stages, I-II degrees, risk II. Metabolic cardiomyopathy. Heart failure, grade I, with conservation of ejection fraction (62%). Functional class, grade II (NYHA).Deforming osteoarthritis of the knee 01/25/2018
N/A
Moderate hypertension of the interventricular septum, diastolic dysfunction. Aortofibrosis. Changes in the pulmonary artery.
3-Sep-19
BBS0000-A0900111868082219DDHeart FailureSerum1.0013.00$200.0085 YFemaleNon-Hispanic<-70C22-Aug-19ECG | Heart150/90The sinus rhythm is correct. Heart rate - 78 beats. Violation of the processes of reopolarization of the posterior wall of the left ventricle.Laboratory resultsC-reactive protein (CRP) -0.76 mg /l; Creatine Kinase-MB (CPK-MB) - 11 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 611 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownValsacor (Valsartanum) 80/12.5 mg, Rosuvastatin 10 mg, Sotalolum 120 mg, Spironolactonum 50 mg, Ksarelto 15 mg161 cm 71 kgIschemic heart disease: Exertional angina stable, Functional class III. Diffuse cardiosclerosis, Mitral valve insufficiency, stage II, persistent atrial fibrillation; Heart failure, grade IIA, functional class III (NYHA) while maintaining the ejection fraction of the left ventricle. Essential hypertension, grade II, stage III.Diabetes mellitus, type II 02/01/2006, Diffuse toxic goiter with knot formation 05/01/2015, Chronic kidney disease, stage I:Diabetic nephropathy 05/01/2015, Сhronic obstructive pulmonary disease, group B, in remission 05/01/2015
Amaryl (Glimepiride) 01/01/2006, Mercazolil 05/01/2015
Aortocardiosclerosis. Slight left ventricular myocardial hypertrophy with reduced systolic function. Enlarged atrial cavity. Tricuspid valve failure, stage III. Pulmonary hypertension.
19-Aug-19
BBS0000-A0900111870091019DDHeart FailureSerum1.0014.00$200.0040 YFemaleNon-Hispanic<-70C10-Sep-19ECG | Heart150/80Mitral valve-N; Wall of L. ventricle-N; EF-56%; Contractility of L. ventricle-N; Cavity of the ventricle is enlarged; Aortic valve-N; Moderate fibrosis; Systolic opening of the aortic valve- complete 1.7; Aorta-H; R. atrium-N; Pericardium - N.Laboratory resultsC-reactive protein (CRP) - 434.16 mg/l; Creatine Kinase - MB (CPK-MB) - 6 U/l; Troponin I - <0.1 ng/ml; NT-proBNP - 166.8 pg/ml10-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCardiomagnyl (Acetylsalicylicum asid)162 cm 79 kgIschemic heart disease: cardiosclerosis. Heart failure, grade I. Functional class, grade II (NYHA).N/A
N/A
BBS0000-A0900111909082219DDHeart FailureSerum1.0014.00$200.0068 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart160/90Sinus rhythm, the electrical axis of the heart is deflected to the left, signs of left ventricular hypertrophyLaboratory resultsC-reactive protein (CRP) -17.01 mg/l; Creatine kinase-MB (CPK-MB) - 12 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 217.6 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownDifors (Valsartan + Amlodipine ) 160/5 mg, Atoris (atorvastatin calcium) 20 mg,174 cm 69 kgIschemic heart disease: diffuse cardiosclerosis. Mitral valve insufficiency. Heart failure, grade II functional class III (NYHA)Podagra
Allopurinol 01/01/2017
Satisfactorily
21-Aug-19
BBS0000-A0900111937090219DDHeart FailureSerum1.0015.00$200.0076 YMaleNon-Hispanic<-70C02-Sep-19ECG | Heart120/70Heart is enlarged across. Reinforced pattern in the lungs.Laboratory resultsC-reactive protein (CRP) -11.04 mg/l; Creatine Kinase-MB ( CPK-MB) - 18 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 2213 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownTorasemide 10 mg, Lasix (Furosemide) 4.0 ml, Spironolactonum 25 mg, Enalapril 2.5 mg173 cm 101 kgIschemic heart disease: diffuse cardiosclerosis. Aortic valve prosthesis (2009). Mitral valve and tricuspid valve insufficiency. Chronic pulmonary hypertension. Heart failure, grade IIB, Functional class, grade III-IV (NYHA) with ejection fraction.Ischemic heart disease; Aortic valve prosthesis 01/01/2009, Atrial fibrillation 01/01/2009
Warfarinum 01/01/2009
Atrial fibrillation with a heart rate of 64-82, blockade of the left leg of the bundle of His, expressed changes in the myocardium.
2-Sep-19
Systolic function is reduced. Arrhythmia. Aortic valve prosthesis. Expansion of the left atrium. Mitral valve insufficiency, stage II, tricuspid valve insufficiency, stage III.
2-Sep-19
BBS0000-A0900111978091019DDHeart FailureSerum1.0014.00$200.0069 YFemaleNon-Hispanic<-70C10-Sep-19ECG | Heart140/85Laboratory resultsC-reactive protein (CRP) - 27.59 mg/l; Creatine Kinase - MB (CPK-MB) - 9 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 4077 pg/ml10-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCarvedilol 6.25 mg169 cm 78 kgIschemic heart disease. Heart failure, grade I. Functional class II (NYHA).N/A
N/A
BBS0000-A0900111979082219DDHeart FailureSerum1.0013.00$200.0064 YMaleNon-Hispanic<-70C22-Aug-19ECG | Heart110/75Atrial flutter, irregular shape 2:1; 3:1; 4:1.Laboratory resultsC-reactive protein (CRP) - 25.09 mg/l; Creatine kinase-MB (CPK-MB) -9 U/l; Troponin I- <0.1 ng/ml; NT-proBNP - 1549 pg/ml22-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownPlavix (Clopidogrel) 75 mg, Coryol ( Carvedilol ) 20 mg, Renial 50 mg, Crestor (Rosuvastatin) 20 mg, Cordarone (Amiodarone) 400 mg, Entresto (Valsartan + Sacubitril) 100 mg, Xarelto (Rivaroxaban) 20 mg169 cm 84 kgIschemic heart disease: stable exertional angina, functional class, grade II. Diffuse and postinfarction cardiosclerosis. Relative insufficiency of the mitral valve. Permanent atrial fibrillation. Condition after coronary artery bypass grafting. Pulmonary hypertension, stage I. Heart failure, grade IIA, functional class III (NYHA).Essential hypertension 2000, Acute M.I. 2003, Thromboembolism pulmonary artery 2019, Сoronary artery bypass grafting/ mitral valve repair w/ support ring. Secondary anemia. 2019, Diabetes mellitus II. Lower extremity obliteration cardiosclerosis, stage IV 2008
Gyno-Tardyferon (Ferrous sulfate, Folic acid) 05/20/2019, Metfogamma (Metformin) 05/20/2019
End-diastolic dimension LV 63 mm; end-systolic dimension 49 mm; systolic volume 91ml; EF 45%; left atrium 44 mm; right auricle 46 mm; Сoronary artery bypass grafting-3. Mitral valve repair with support ring. Left ventricular myocardial hypertrophy.
21-Aug-19
BBS0000-A0900111980082919DDHeart FailureSerum1.0015.00$200.0080 YFemaleNon-Hispanic<-70C29-Aug-19ECG | Heart180/100Sinus heart rhythm is slow, blockade of the left leg of the bundle of His, individual extrasystoles, pronounced changes in the myocardium, an increase in the left ventricle.Laboratory resultsC-reactive protein (CRP) -0.69 mg/l; Creatine Kinase-MB (CPK-MB) -18 U/l; Troponin I <0.1 ng/ml; NT-proBNP-1526 pg/ml29-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownSydnopharm (Molsidominum) 2 mg, Bisoprolol 5 mg, Torasemide 10 mg, Valsartan 320 mg, Cordarone (Amiodarone) 200 mg, Cardiomagnyl 75 mg169 cm 94 kgIschemic heart disease: diffuse cardiosclerosis. Extrasystolic arrhythmia, complete blockade of the left leg of the bundle of His. Arterial hypertension, grade II, stage III; Hypertensive heart disease. Mitral defect with a predominance of stenosis, stage II. Heart failure, grade IIA, Functional class, grade III (NYHA) with reduced ejection fraction (37%).Chronic obstructive pulmonary disease 01/01/2010, Diabetes mellitus, type II 01/01/2015
N/A
Extrasystolic arrhythmia. Expansion of all parts of the heart. Hypertrophy of the walls of the left ventricle, systolic-diastolic dysfunction. Mitral disease with a predominance of stenosis.
21-Aug-19
The heart is enlarged across, the roots of the lungs are stagnant. Free fluid in the pleural cavity was not detected.
21-Aug-19
BBS0000-A0900111984082919DDHeart FailureSerum1.0015.00$200.0064 YFemaleNon-Hispanic<-70C29-Aug-19ECG | Heart160/90The ejection fraction is 57%. Cavities not enlarged, systolic dysfunction.Laboratory resultsC-reactive protein (CRP) - 0.74 mg/l; Creatine Kinase-MB (CPK-MB) - 6 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 106.1 pg/ml29-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBisoprolol 5 mg, Spironolactonum 50 mg, Corvitin (Quercetin) 0.5 g, Enalapril 5 mg168 cm 91 kgIschemic heart disease: exertional angina, functional class, grade II. Diffuse cardiosclerosis. Mitral valve insufficiency, grade I. Arterial hypertension,grade II, stage II. Left ventricular myocardial hypertrophy. Heart failure, grade IIA, functional class, grade II (NYHA) with preserved systolic function. Diastolic dysfunction.Diabetes mellitus, type II 01/01/2013
Diaformin (Metformin) 01/01/2013, Diaglizide (Gliclazide) 01/01/2013
Dilation of the right ventricle, fibro-sclerotic valve changes. Mitral valve insufficiency, stage I. Diastolic dysfunction.
21-Feb-17
Asymmetry of contractility of the posterior wall of the left ventricle after exercise. Aortic fibrosis. The systolic function of the left ventricle is preserved. After insignificant physical activity, asymmetry appeared, contraction of the left ventricular walls.
2-Sep-19
BBS0000-A0900111991090219DDHeart FailureSerum1.0015.00$200.0072 YFemaleNon-Hispanic<-70C02-Sep-19ECG | Heart160/80Reinforced broncho-pulmonary pattern, stagnant rootsLaboratory resultsC-reactive protein (CRP) - 1.35 mg/l; Creatine Kinase-MB (CPK-MB) - 10 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 921.4 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownXipagamma (Xipamid) 10 mg, Valsartan 160 mg, Torasemide 10 mg, Warfarinum 2.5 mg168 cm 71 kgIschemic heart disease: diffuse cardiosclerosis. Persistent form of atrial fibrillation. Arterial hypertension, grade II, stage I, risk IV. Heart failure, grade IIA, functional class, grade II-III (NYHA).Diabetes mellitus, type II 01/01/2011, Cholecystectomy 01/01/2009
Apidra (Insulinum glulisinum) 01/01/2018, Lantus (Insulin glargine) 01/01/2018, Difors (Valsartan, Amlodipine ) 01/01/2017, Roxera (Rosuvastatin) 01/01/2017
Atrial fibrillation, pronounced diffuse changes in the myocardium
2-Sep-19
Systolic fibrillation persists. Combined aortic defect, stage I-II. Aortic stenosis, grade I-II. Hypertrophy of the walls of the left ventricle.
2-Sep-19
BBS0000-A0900111993091019DDHeart FailureSerum1.0011.00$200.0063 YFemaleNon-Hispanic<-70C10-Sep-19ECG | Heart140/80Laboratory resultsC-reactive protein (CRP) - 213.21 mg/l; Creatine Kinase - MB (CPK-MB) - 23 U/l; Troponin I - <0.1ng/ml; NT-proBNP - 602.4 pg/ml10-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownBisoprolol 5 mg168 cm 71 kgIschemic heart disease. Heart failure, grade I. Functional class II (NYHA).N/A
N/A
BBS0000-A0900111994082719DDHeart FailureSerum1.0015.00$200.0058 YFemaleNon-Hispanic<-70C27-Aug-19ECG | Heart160/90Paroxysm of atrial fibrillationLaboratory resultsC-reactive protein (CRP) -7 mg/l; Creatine Kinase-MB (CPK-MB) -11 U/l; Troponin I <0.1 ng/ml; NT-proBNP-784 pg/ml27-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCardiomagnyl (Acetylsalicylic acid ) 75 mg, Nebivolol 5 mg, Furosemide 40 mg168 cm 83 kgIschemic heart disease: paroxysm of atrial fibrillation. Heart failure, grade IIA with saved ejection fraction of left ventricular, functional class III (NYHA).N/A
N/A
Hypertrophy of the upper third of the interventricular septum. Contractility is not impaired. Left ventricular ejection fraction - 54%. Combined aortic malformation with insufficiency, stage II. Regurgitation at the mitral valve I, tricuspid valve I.
27-Aug-19
Sinus rhythm, electrical axis of the heart, left ventricular hypertrophy
21-Aug-19
BBS0000-A0900112032082919DDHeart FailureSerum1.0015.00$200.0071 YFemaleNon-Hispanic<-70C29-Aug-19ECG | Heart95/60In the lungs are stagnant, stagnant, extended roots. Right dimming to III ribs due to free fluidLaboratory resultsC-reactive protein (CRP) - 6.46 mg/l; Creatine Kinase-MB (CPK-MB) - 10 U/l; Troponin I <0.102 ng/ml; NT-proBNP - 18169 pg/ml29-Aug-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownEplerenone 25 mg, Torasemide 4.0 ml, Furosemide 4.0 ml, Carvedilol 25 mg, Xarelto (Rivaroxaban) N/A, Corvitin (Quercetin) 0.5 g163 cm 114 kgIschemic heart disease: combined heart disease, persistent atrial fibrillation. Heart failure, grade IIA, functional class, grade III-IV (NYHA) with reduced ejection fraction 38%.Cholecystectomy 01/01/2009, Right-sided pneumonia 08/23/2019
Levofloxacin 08/23/2019, 08/30/2019, Fluconazole 08/23/2019, 08/30/2019, Dexona (Dexamethason), 08/23/2019, 08/30/2019
Normosystolic atrial fibrillation, heart rate 64-68, pronounced diffuse changes in the myocardium with its systolic overload
8/23/2019
Systolic function of the heart is reduced. Aortic stenosis. Left atrial dilation. Left ventricular myocardial hypertrophy.
30-Aug-19
BBS0000-A0900112284090219DDHeart FailureSerum1.0013.00$200.0055 YMaleNon-Hispanic<-70C02-Sep-19ECG | Heart110/70Laboratory resultsC-reactive protein (CRP) -30.92 mg/l; Creatine Kinase-MB (CPK-MB) - 13 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 5785 pg/ml2-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownYuperio 50 mg, Trifas (Torasemide ) 10 mg, Ksarelto 20 mg, Koriol 6.25 mg174 cm 88 kgIschemic heart disease: diffuse cardiosclerosis. Relative insufficiency of mitral valve, stage III and tricuspid valve, stage II-III. Permanent tachy-normal form of atrial fibrillation. Heart failure, grade IIA, Functional class, grade III (NYHA) with reduced ejection fraction.Gouty arthritis 01/01/1979
Adenuric (Febuxostatum)
Atrial fibrillation with a heart rate of 180-86 beats per minute.
30-Aug-19
BBS0000-A0900112285090419DDHeart FailureSerum1.0013.00$200.0070 YMaleNon-Hispanic<-70C04-Sep-19ECG | Heart140/90Laboratory resultsC-reactive protein (CRP) -24.12 mg/l; Creatine Kinase-MB (CPK-MB) - 9 U/l; Troponin I <0.1 ng/ml; NT-proBNP - 1571 pg/ml4-Sep-19HIV I & II | HBV | HCV ResultsNegative$200.00UnknownCordarone (Amiodarone) 200 mg, Vazoklin 20 mg, Torasemide 10 mg174 cm 96 kgIschemic heart disease: diffuse cardiosclerosis. Relative mitral valve insufficiency. Supraventricular extrasystole. Heart failure, grade II A functional class III (NYHA) with preserved ejection fraction. Secondary metabolic cardiomyopathy.Arterial hypertension, grade II stage III, Erosive gastritis with reduced acid-forming function N/A, Secondary Normochromic Anemia N/A, Chronic renal disease stage 2, diabetic nephropathy, chronic renal failure N/A, Diabetes mellitus type II, moderate severity 01/01/2015
Nolpaza (Pantoprazolum) 08/30/2019, Gaviscon (Calcium carbonate, Sodium alginate, Sodium hydrocarbonate) 08/30/2019, Glibenclamide 09/03/2018
Sinus rhythm. Heart rate - 86 beats per minute. Symptoms load on the left ventricle. Violation of repolarization of the basal parts of the lateral wall of the left ventricle.
22-Aug-19
BBS0000-AI900090930083019DDHeart FailureUnited StatesSerum1.251.00$75.0079 YMaleNon-Hispanic<-70C30-Aug-19DiagnosisCongestive Heart Failure stage 4 (CHF)$75.00Unknown397 pg/mL
BNP
BBS0000-AI900341749100519DDHeart FailureUnited StatesSerum1.001.00$75.0043 YMaleNon-Hispanic<-70C05-Oct-19DiagnosisCongestive Heart Failure stage 2 (CHF)$75.00Unknown
BBS0000-AI900357226120219DDHeart FailureUnited StatesSerum1.201.00$75.0086 YMaleNon-Hispanic<-70C02-Dec-19CHF Stage4Abbott Architect | CMIA | Chemiflex3085 pg/mLBNP$75.00Unknown
BBS0000-AI900380268030420DDHeart FailureUnited StatesSerum2.201.00$75.00FemaleNon-Hispanic<-70C04-Mar-20Abbott Architect | CMIA | Chemiflex162BNP$75.00Unknown
BBS0000-AI900388257021820DDHeart FailureUnited StatesSerum1.001.00$75.00FemaleNon-Hispanic<-70C18-Feb-20CHF Stage3Abbott Architect | CMIA | Chemiflex486 pg/mLBNP$75.00Unknown
BBS0000-AI900399831051720DDHeart FailureUnited StatesSerum1.001.00$75.0056 YMaleNon-Hispanic<-70C17-May-20CHF Stage3Abbott Architect | CMIA | Chemiflex2,415 pg/mLBNP$75.00Unknown
BBS0000-AI900401022042920DDHeart FailureUnited StatesSerum1.001.00$75.0071 YMaleNon-Hispanic<-70C29-Apr-20Abbott Architect | CMIA | Chemiflex4,080BNP$75.00Unknown
RUI0000-AI900088647041119DDHeart FailureUnited StatesRaw Urine0.5022.00$75.0060 YFemaleNon-Hispanic<-70C11-Apr-19ResultCHF$75.00Unknown
RUI0000-AI900088648041019DDHeart FailureUnited StatesRaw Urine0.5018.00$75.0079 YMaleUnknown<-70C10-Apr-19ResultCHF$75.00Unknown
URI0000-AI900031452032719DDHeart FailureUnited StatesUrine0.5021.00$75.0071 YMaleNon-Hispanic<-70C27-Mar-19ResultCHF$75.00Unknown
URI0000-AI900092607031819DDHeart FailureUnited StatesUrine0.5023.00$75.0086 YFemaleNon-Hispanic<-70C18-Mar-19ResultCHF$75.00Unknown
URI0000-AI900092847031419DDHeart FailureUnited StatesUrine0.5019.00$75.0067 YMaleNon-Hispanic<-70C14-Mar-19ResultCHF$75.00Unknown
URI0000-AI900092848031619DDHeart FailureUnited StatesUrine0.5020.00$75.0087 YFemaleNon-Hispanic<-70C16-Mar-19ResultCHF$75.00Unknown
URI0000-AI900092849031719DDHeart FailureUnited StatesUrine0.5020.00$75.0075 YFemaleNon-Hispanic<-70C17-Mar-19ResultCHF$75.00Unknown

Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.

Please read carefully before purchasing:

Clinical specimens for research use only.

Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.

If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341

These products are supplied without warranty for suitability for specific applications or analytical determinations.

Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.